Can a drug stop muscle loss in lung cancer? new trial aims to find out
NCT ID NCT07663630
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical function, like walking distance and daily activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ponsegromab
What this could lead to
If it works, this could point toward a treatment to help people with lung cancer maintain muscle strength and daily function.
What could go wrong
This is a very early Phase 1b trial with only 80 participants, so results may not lead to a proven therapy. The drug may not improve muscle mass or function as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••